ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA) (“ArTara” or the “Company”), a development-stage clinical biopharmaceutical company developing treatments for...

ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics Shares of ArTara to commence trading on Nasdaq under new ticker symbol “TARA” effective January 10, 2020 Company completes previously announced equity financing of $42.5 million concurrently with the...

ArTara Therapeutics Announces the Appointment of Richard Levy, M.D., and Gregory Sargen to its Board of Directors NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- ArTara Therapeutics (“ArTara” or the “Company”), a clinical-stage company developing treatments for rare and specialty diseases with significant unmet...